United States patent 3,459,738 was granted on 5 August 1969 to Henri Morren of Forest, Belgium, and assigned to UCB. Its title is plain: N-substituted lactams. Its chemistry is plainer still. Deprotonate a lactam with an alkali metal hydride, then alkylate the resulting anion with an omega-chloroacylamide. One product of that reaction is 2-(2-oxopyrrolidin-1-yl)acetamide. Six decades later, an entire class of research compounds is named after the last two syllables of the name that molecule was sold under.
The racetam skeleton is one of the smallest scaffolds in medicinal chemistry to have acquired its own suffix. What actually defines membership of the family, and what does not, matters to anyone who has to source, identify or assay these compounds.
One lactam, one acetamide arm, nothing else
Piracetam is 2-(2-oxopyrrolidin-1-yl)acetamide. PubChem lists it as CID 4843, molecular formula C6H10N2O2, molecular weight 142.16 g/mol, CAS registry number 7491-74-9. The canonical SMILES string is short enough to memorise: C1CC(=O)N(C1)CC(=O)N.
Two functional groups sit on that skeleton. The first is a five-membered lactam, 2-pyrrolidinone, which is a cyclic secondary amide. The second is a primary acetamide tethered to the lactam nitrogen through a single methylene bridge. There is no aromatic ring, no basic amine and no group that ionises at physiological pH. PubChem’s computed XLogP3 value for piracetam is -1.3, placing it firmly on the hydrophilic side.
That is the entire molecule. Its plainness is the reason the family exists. There are only a few places to hang a substituent, and synthetic chemists have systematically tried all of them.
The patent that fixed the synthetic route
Morren’s patent describes two complementary approaches. The first is the alkylation already mentioned: the lactam is converted to its alkali metal salt, which then displaces chloride from an appropriate omega-chloroacylamide. The second runs in the opposite direction, amidating a lactam-N-alkanoic acid with an amine of the general form HN(R’)R”. The worked examples cover pyrrolidones, piperidones and azepines, which shows that ring size was already being treated as a variable in 1964.
Both routes remain recognisable in modern process chemistry. They also make a practical point. The reagents are cheap, the chemistry is old and there is nothing exotic about preparing these compounds. Purity and identity confirmation, not synthetic difficulty, are where the laboratory work sits.
What the word nootropic meant when it was coined
Corneliu Giurgea published The nootropic approach to the pharmacology of the integrative activity of the brain in Conditional Reflex in 1973. That paper is the origin of the term, and the term was defined by a list of behavioural and pharmacological criteria rather than by a molecular target.
The consequence has shaped the field ever since. The class was named for what its founding member was claimed to do, not for what it binds. The chemical family and the pharmacological category were therefore born misaligned: a compound can carry the skeleton without meeting Giurgea’s criteria, and a compound can meet the criteria without carrying the skeleton.
Where the substituents actually go
Three positions have absorbed nearly all the synthetic effort: carbon 4 of the pyrrolidinone ring, the ring nitrogen itself, and the carbon alpha to the acetamide carbonyl. The table compares six well-documented members. Every formula, mass and partition value below is taken from the corresponding PubChem compound record.
| Compound | Change relative to piracetam | Formula | MW (g/mol) | XLogP3 |
|---|---|---|---|---|
| Piracetam | parent scaffold | C6H10N2O2 | 142.16 | -1.3 |
| Oxiracetam | hydroxyl at ring C-4 | C6H10N2O3 | 158.16 | -2.2 |
| Phenylpiracetam | phenyl at ring C-4 | C12H14N2O2 | 218.25 | 0.1 |
| Levetiracetam | ethyl at the acetamide alpha-carbon, (2S) | C8H14N2O2 | 170.21 | -0.3 |
| Nefiracetam | amide N-arylated with 2,6-dimethylphenyl | C14H18N2O2 | 246.30 | 1.4 |
| Aniracetam | acetamide arm replaced by 4-methoxybenzoyl on ring N | C12H13NO3 | 219.24 | 1.6 |
Aniracetam is the awkward case. It has no acetamide arm at all. The ring nitrogen carries a 4-methoxybenzoyl group instead, and the molecule contains one nitrogen rather than two. On a strict reading it is an N-acyl lactam rather than an acetamide, yet nobody disputes its membership. In practice, membership is decided by the 2-oxopyrrolidine ring and by historical lineage.
The racetam skeleton predicts chemistry, not pharmacology
Levetiracetam is the clearest demonstration. Structurally it is piracetam with an ethyl group on the acetamide alpha-carbon and a defined (2S) configuration, a trivially small change. Pharmacologically it went somewhere else entirely.
Lynch and colleagues reported in the Proceedings of the National Academy of Sciences in 2004 that the synaptic vesicle protein SV2A is the brain binding site for levetiracetam. Brain membranes and purified synaptic vesicles from mice lacking SV2A did not bind a tritiated levetiracetam derivative, and no binding was observed at the related isoforms SV2B or SV2C.
Malykh and Sadaie, reviewing the class in Drugs in 2010, divided it into three subgroups on exactly this basis. The first contains piracetam, oxiracetam, aniracetam, pramiracetam and phenylpiracetam. The second contains levetiracetam, seletracetam and brivaracetam, which act through SV2A. The third gathers derivatives whose clinical profile remains unclear. One skeleton, three separate stories.
A family that never settled its own evidence base
Gualtieri and co-workers, writing in Current Pharmaceutical Design in 2002, described piracetam-like nootropics as compounds that have never reached general acceptance despite their tolerability. They attributed the impasse to the complexity of the brain functions involved, the poor predictive value of the available animal tests, and the length and cost of the trials needed to settle the question.
The Cochrane review by Flicker and Grimley Evans was blunter. Piracetam improved global impression scores relative to placebo, but the effect did not appear on more specific cognitive measures, and the reviewers concluded that the published evidence does not support the use of piracetam in people with dementia or cognitive impairment. Any honest account of this family has to include that sentence.
What the skeleton means at the bench
The parent scaffold is an analytical nuisance for predictable reasons. It carries no strong chromophore, so ultraviolet detection ends up in the low-wavelength region where solvents and excipients interfere. It is very polar, so it elutes close to the void volume on conventional reversed-phase columns. Aqueous solubility is high and partition into organic solvents is poor, which complicates liquid-liquid extraction from complex matrices.
Acylated members behave differently. The methoxybenzoyl group of aniracetam supplies both chromatographic retention and a usable absorbance band. Method development therefore has to be done per compound rather than per family, and each method needs anchoring to a characterised analytical reference standard with a batch-specific certificate of analysis, not to a retention time copied from a paper.
Frequently asked questions
What is the racetam skeleton?
The racetam skeleton is a 2-oxopyrrolidine ring, also called 2-pyrrolidinone, attached through its nitrogen to a short acyl or acetamide substituent. The prototype is piracetam, 2-(2-oxopyrrolidin-1-yl)acetamide, molecular formula C6H10N2O2 and molecular weight 142.16 g/mol according to PubChem. Family membership is defined by that ring, not by a shared molecular target.
Is levetiracetam a racetam?
Structurally, yes. Levetiracetam is (2S)-2-(2-oxopyrrolidin-1-yl)butanamide, which is piracetam carrying an ethyl substituent on the acetamide alpha-carbon. Its pharmacology is separate. Lynch and colleagues identified the synaptic vesicle protein SV2A as its brain binding site in 2004, a target not shared with the older members of the family.
Who first synthesised piracetam?
The compound came out of work by Henri Morren at UCB in Belgium. United States patent 3,459,738, titled N-substituted lactams, carries a priority date of 6 August 1964, a filing date of 3 August 1965 and a grant date of 5 August 1969. It describes alkylating an alkali metal lactam salt with an omega-chloroacylamide.
Why do racetams differ so much in polarity?
Because substitution changes the balance between the polar core and any added hydrophobic surface. PubChem’s computed XLogP3 values run from -2.2 for oxiracetam, which carries an extra hydroxyl group, to 1.6 for aniracetam, which carries an aromatic methoxybenzoyl group. That spread of nearly four log units governs chromatographic retention, solubility and extraction behaviour.
References
- Morren H., N-substituted lactams, US Patent 3,459,738, UCB, granted 1969
- Giurgea C., The nootropic approach to the pharmacology of the integrative activity of the brain, Conditional Reflex, 1973
- PubChem, Piracetam, CID 4843, National Library of Medicine
- Gualtieri F. et al., Design and study of piracetam-like nootropics, Current Pharmaceutical Design, 2002
- Lynch B.A. et al., The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam, PNAS, 2004
- Malykh A.G., Sadaie M.R., Piracetam and piracetam-like drugs, Drugs, 2010
- Flicker L., Grimley Evans G., Piracetam for dementia or cognitive impairment, Cochrane Database of Systematic Reviews, 2001
Research use only. Nonsensia Lab supplies analytical reference standards for laboratory and research applications. This article is published for scientific and educational purposes. It is not medical advice, it does not describe any use in humans, and nothing in it should be read as a recommendation to administer any substance to a person or animal.
Filed under: Chemistry & Discovery
This article is part of our guide to Where Research Compounds Come From: Discovery, Synthesis and Structure.
The compound discussed in this article is available as an analytical reference standard: Aniracetam ≥99% – Analytical Reference Standard | CAS 72432-10-1.